ERBB2 and ovarian carcinoma: In epithelial tumors, especially in breast and ovarian cancer [16–18], overexpression of the transmembrane receptor tyrosine kinase HER2/neu (c-erb-B2) was originally associated with a deleterious prognosis due to its involvement in oncogenic transformation and metastatic potential [19].